Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pharmather Holdings Ltd PHRRF


Primary Symbol: C.PHRM

PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The Company is also commercializing PharmaPatch (microneedle patch) with its partners to deliver psychedelics and drugs to treat infectious diseases.


CSE:PHRM - Post by User

Comment by Itistooon Nov 13, 2024 12:02pm
69 Views
Post# 36310479

RE:Great NEWS!!!!

RE:Great NEWS!!!!The meeting is good I guess, maybe should have happened long ago if they weren't confident with their submissions. But this is a pathetic excuse to delay the meeting, the FDA was willibg to meet the day after Thanksgiving our guys were not.. I doubt they will get the week after as they requested but we will soon find out. This will clear things up for them but will add to the delay as once they have the info needed from the FDA they will have to resubmit their amendments and then the FDA will have the 3 month review period from that date.
<< Previous
Bullboard Posts
Next >>